Table 1.

Characteristics of the study group.

Patient	Sex	Age (years)	ESR (mm/h)	CRP (mg/l)	Medication	Disease activity	Organ involvement	cANCA titre
1	Female	21	10	<5	Prednisolone	Remission	ENT	Neg
2	Male	33	18	″5	Prednisolone	Remission	ENT	Neg
3	Female	29	10	<5	Trim-Sulpha	Remission	ENT, lung	1 : 32
4	Male	54	47	26	CyclophosphamidePrednisolone	Active	kidney, ENT	1 : 64
5	Male	65	11	<5	Prednisolone	Remission	ENT, kidney	1 : 16
6	Male	59	17	<5	Trim-Sulpha	Remission	ENT, lung	Neg
7	Male	60	34	11	Prednisolone	Remission	ENT, kidney	1 : 16
8	Male	23	61	29	Cyclophosphamide Prednisolone	Active	ENT, kidney	1 : 128
9	Male	36	>100	161	PrednisoloneTrim-Sulpha	Active	lung, kidney	1 : 512
10	Female	78	21	13	Prednisolone	Remission	ENT	Neg
11	Female	35	10	14	None	Remission	ENT, kidney	1 : 16
12	Female	54	96	62	CyclophosphamidePrednisolone	Active	ENT, kidney, lung	1 : 512
13	Female	52	″8	″7	None	Remission	ENT, lung	1 : 16
14	Female	25	28	62	CyclophosphamidePrednisolone	Active	Lung, kidney	1 : 128

WG patients were classified as having active disease or being in remission based on clinical judgement¸ the Birmingham Vasculitis Activity Score as well as levels of C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Trim-Sulpha, trimethoprim-sulphametoxazol; ENT, ear, nose and throat; cANCA, cytoplasmic antineutrophil cytoplasmic antibodies. Organ involvement in those in remission represents previous involvement during active disease.